Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21540903 | 0.89 | HIF1A (0.67) | HIF1ASLC29A1 | |
| SCHEMBL14616840 | 0.85 | PNP (0.54) | ADORA3 | |
| SCHEMBL3968756 | 0.85 | SLC29A1 (0.47) | HIF1AADORA3SLC29A1 | |
| SCHEMBL444962 | 0.83 | HIF1A (0.58) | HIF1AADORA3POLBENPP1P2RY1 | |
| SCHEMBL439242 | 0.82 | POLB (0.67) | HIF1APOLBENPP1P2RY1 | |
| SCHEMBL10021398 | 0.82 | POLB (0.67) | HIF1APOLBENPP1P2RY1 | |
| SCHEMBL16359945 | 0.82 | POLB (0.67) | HIF1APOLBENPP1P2RY1 | |
| SCHEMBL6662994 | 0.82 | ADORA3 (0.71) | ADORA3 | |
| SCHEMBL6663002 | 0.82 | ADORA3 (0.71) | ADORA3 | |
| Iodide SCHEMBL16244633 | 0.81 | POLB (0.66) | HIF1APOLBENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | ENZON PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018010-A1 | POLYMERIC CONJUGATES OF ADENINE NUCLEOSIDE ANALOGS | VEGFA, MKI67, PCNA | HIF1A 922/4885ADORA3 109/4885SLC29A1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.